See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Basketball
Vatican
Wrestling
Baseball
Donald Trump
MLS
Tennis
Hockey
Israel-Hamas Conflict
Elon Musk
Hamas
Published • loading... • Updated

Zydus and Beihai Biotech sign an exclusive licensing, supply and commercialization agreement for BEIZRAY (Albumin Solubilized Docetaxel Injection), a 505(B)(2) product for the US market - Passionate In Marketing

Summary by passionateinmarketing.com
Zydus Lifesciences Ltd., a global innovation driven healthcare company announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE has entered into an exclusive licensing, supply and commercialization agreement with Zhuhai Beihai Biotech Co., Ltd for BEIZRAY (Albumin Solubilized Docetaxel Injection), a 505(B)(2) product for the US market.  Under the terms of this agreement, Beihai […] The post Zydus and Beihai Biotech sign an exclu…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
passionateinmarketing.compassionateinmarketing.com

Zydus and Beihai Biotech sign an exclusive licensing, supply and commercialization agreement for BEIZRAY (Albumin Solubilized Docetaxel Injection), a 505(B)(2) product for the US market - Passionate In Marketing

Zydus Lifesciences Ltd., a global innovation driven healthcare company announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE has entered into an exclusive licensing, supply and commercialization agreement with Zhuhai Beihai Biotech Co., Ltd for BEIZRAY (Albumin Solubilized Docetaxel Injection), a 505(B)(2) product for the US market.  Under the terms of this agreement, Beihai […] The post Zydus and Beihai Biotech sign an exclu…

Read Full Article
Express PharmaExpress Pharma

Zydus Lifesciences partners with Zhuhai Beihai Biotech for BEIZRAY commercialisation in the US - Express Pharma

Zydus Lifesciences has announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing, supply, and commercialisation agreement with Zhuhai Beihai Biotech Co., Ltd for BEIZRAY (Albumin Solubilized Docetaxel Injection) in the US market. BEIZRAY is a 505(B)(2) product, approved for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and nec…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Express Pharma broke the news in on Friday, February 14, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Innovation

Innovation

United States

United States

News
For You
Search
BlindspotLocal